Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) on January 10, 2024. The meeting focused on the company's Investigational New Drug (IND) resubmission for CMND-100, a compound designed for the treatment of Alcohol Use Disorder (AUD) using a novel psychedelic-based therapy. The CEO of Clearmind, Dr. Adi Zuloff-Shani, expressed satisfaction with the meeting's outcome and the company's eagerness to progress with the U.S. regulatory process. CMND-100's active ingredient, MEAI, has shown potential in reducing the desire for alcohol consumption while providing a euphoric experience similar to alcohol. Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines and holds fifteen patent families in its intellectual portfolio. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) on January 10, 2024. The meeting focused on the company's Investigational New Drug (IND) resubmission for CMND-100, a compound designed for the treatment of Alcohol Use Disorder (AUD) using a novel psychedelic-based therapy. The CEO of Clearmind, Dr. Adi Zuloff-Shani, expressed satisfaction with the meeting's outcome and the company's eagerness to progress with the U.S. regulatory process. CMND-100's active ingredient, MEAI, has shown potential in reducing the desire for alcohol consumption while providing a euphoric experience similar to alcohol. Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines and holds fifteen patent families in its intellectual portfolio. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 宣布于2024年1月10日完成了与美国食品药品监督管理局（FDA）的A型会议。会议重点讨论了该公司重新提交的 CMND-100 的研究性新药（IND），这是一种专为使用新型迷幻药疗法治疗酒精使用障碍（AUD）而设计的化合物。Clearmind首席执行官阿迪·祖洛夫-沙尼博士对会议结果以及该公司渴望在美国监管程序方面取得进展表示满意。CMND-100 的活性成分 MEAI 已显示出减少饮酒欲望的潜力，同时提供类似于酒精的欣快体验。Clearmind的目标是将其迷幻剂类化合物作为受管制药物进行商业化，并在其知识组合中拥有15个专利家族。该公司的股票在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，股票代码分别为 “CMND” 和 “CWY”。
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 宣布于2024年1月10日完成了与美国食品药品监督管理局（FDA）的A型会议。会议重点讨论了该公司重新提交的 CMND-100 的研究性新药（IND），这是一种专为使用新型迷幻药疗法治疗酒精使用障碍（AUD）而设计的化合物。Clearmind首席执行官阿迪·祖洛夫-沙尼博士对会议结果以及该公司渴望在美国监管程序方面取得进展表示满意。CMND-100 的活性成分 MEAI 已显示出减少饮酒欲望的潜力，同时提供类似于酒精的欣快体验。Clearmind的目标是将其迷幻剂类化合物作为受管制药物进行商业化，并在其知识组合中拥有15个专利家族。该公司的股票在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，股票代码分别为 “CMND” 和 “CWY”。
有用
没用